Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

CELCBullishCorporate Developmentsnews

High materiality9/10

Celcuity's VIKTORIA-1 Trial Success Boosts Stock Amid Strong Momentum

May 4, 2026, 7:26 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The positive trial results provide a strong catalyst for further stock appreciation. Historical precedents indicate similar biotech trials have positively impacted stock prices significantly.

AI summary

What happened, with direct paths to the underlying reporting

Celcuity Inc. shares surged 18.98% following positive results from its Phase 3 VIKTORIA-1 trial. The trial's achievement of its primary endpoint positions Celcuity favorably in the oncology market as it prepares to submit findings to the FDA, which could drive further stock gains.

CELC shares jumped 18.98% following positive Phase 3 trial results.
VIKTORIA-1 trial met primary endpoint, improving PFS for breast cancer patients.
FDA submission planned by July 2026 for gedatolisib treatment approval.
Stock shows strong momentum, trading above key moving averages.
Current trading near 52-week high signals strong investor interest.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Celcuity's VIKTORIA-1 Trial Success Boosts Stock Amid Strong Momentum

Celcuity Q2 loss narrows; potential near-term upside on beat

Celcuity receives FDA approval for its first product in advanced breast cancer

Celcuity reports Phase 3 superiority for gedatolisib regimens in VIKTORIA-1

Celcuity plunges after trial results, underscoring data risk in its cancer program